Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration

Zi-Rong Chen; Chen-Han Chueh; Nai-Jung Chiang; Yi-Wen Tsai

doi:10.1186/s12962-023-00473-5

Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration

Zi-Rong Chen, Chen-Han Chueh, Nai-Jung Chiang^*, Yi-Wen Tsai^*

^*Corresponding author for this work

Institute of Health and Welfare Policy

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

In December 2022, the Taiwan National Health Insurance Administration (NHIA) announced the reimbursement of three dosages of pemigatinib 4.5 mg, 9 mg, and 13.5 mg for treating advanced intrahepatic cholangiocarcinoma (ICC) with fibroblast growth factor receptor 2 (FGFR2) fusions/rearrangements and set the reimbursement price for pemigatinib 4.5 mg at NT$6600. This study aims to analyze the cost-effectiveness of pemigatinib 13.5 mg as a second-line treatment compared to mFOLFOX and 5-FU chemotherapy for advanced ICC patients with FGFR2 fusions/rearrangements from the perspective of Taiwan’s NHIA.

Original language	American English
Journal	Cost Effectiveness and Resource Allocation
Volume	21
Issue number	1
DOIs	https://doi.org/10.1186/s12962-023-00473-5
State	Published - 11 Sep 2023

Access to Document

10.1186/s12962-023-00473-5

Fingerprint

Dive into the research topics of 'Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration'. Together they form a unique fingerprint.

Cite this

Chen, Z.-R., Chueh, C.-H., Chiang, N.-J., & Tsai, Y.-W. (2023). Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration. Cost Effectiveness and Resource Allocation, 21(1). https://doi.org/10.1186/s12962-023-00473-5

Chen, Zi-Rong ; Chueh, Chen-Han ; Chiang, Nai-Jung et al. / Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration. In: Cost Effectiveness and Resource Allocation. 2023 ; Vol. 21, No. 1.

@article{d411115e389b4bf188aa26b3504bfd2d,

title = "Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration",

abstract = "In December 2022, the Taiwan National Health Insurance Administration (NHIA) announced the reimbursement of three dosages of pemigatinib 4.5 mg, 9 mg, and 13.5 mg for treating advanced intrahepatic cholangiocarcinoma (ICC) with fibroblast growth factor receptor 2 (FGFR2) fusions/rearrangements and set the reimbursement price for pemigatinib 4.5 mg at NT$6600. This study aims to analyze the cost-effectiveness of pemigatinib 13.5 mg as a second-line treatment compared to mFOLFOX and 5-FU chemotherapy for advanced ICC patients with FGFR2 fusions/rearrangements from the perspective of Taiwan{\textquoteright}s NHIA.",

author = "Zi-Rong Chen and Chen-Han Chueh and Nai-Jung Chiang and Yi-Wen Tsai",

year = "2023",

month = sep,

day = "11",

doi = "10.1186/s12962-023-00473-5",

language = "American English",

volume = "21",

journal = "Cost Effectiveness and Resource Allocation",

issn = "1478-7547",

publisher = "BioMed Central Ltd.",

number = "1",

}

Chen, Z-R, Chueh, C-H, Chiang, N-J & Tsai, Y-W 2023, 'Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration', Cost Effectiveness and Resource Allocation, vol. 21, no. 1. https://doi.org/10.1186/s12962-023-00473-5

Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration. / Chen, Zi-Rong; Chueh, Chen-Han; Chiang, Nai-Jung et al.
In: Cost Effectiveness and Resource Allocation, Vol. 21, No. 1, 11.09.2023.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration

AU - Chen, Zi-Rong

AU - Chueh, Chen-Han

AU - Chiang, Nai-Jung

AU - Tsai, Yi-Wen

PY - 2023/9/11

Y1 - 2023/9/11

N2 - In December 2022, the Taiwan National Health Insurance Administration (NHIA) announced the reimbursement of three dosages of pemigatinib 4.5 mg, 9 mg, and 13.5 mg for treating advanced intrahepatic cholangiocarcinoma (ICC) with fibroblast growth factor receptor 2 (FGFR2) fusions/rearrangements and set the reimbursement price for pemigatinib 4.5 mg at NT$6600. This study aims to analyze the cost-effectiveness of pemigatinib 13.5 mg as a second-line treatment compared to mFOLFOX and 5-FU chemotherapy for advanced ICC patients with FGFR2 fusions/rearrangements from the perspective of Taiwan’s NHIA.

AB - In December 2022, the Taiwan National Health Insurance Administration (NHIA) announced the reimbursement of three dosages of pemigatinib 4.5 mg, 9 mg, and 13.5 mg for treating advanced intrahepatic cholangiocarcinoma (ICC) with fibroblast growth factor receptor 2 (FGFR2) fusions/rearrangements and set the reimbursement price for pemigatinib 4.5 mg at NT$6600. This study aims to analyze the cost-effectiveness of pemigatinib 13.5 mg as a second-line treatment compared to mFOLFOX and 5-FU chemotherapy for advanced ICC patients with FGFR2 fusions/rearrangements from the perspective of Taiwan’s NHIA.

U2 - 10.1186/s12962-023-00473-5

DO - 10.1186/s12962-023-00473-5

M3 - Article

SN - 1478-7547

VL - 21

JO - Cost Effectiveness and Resource Allocation

JF - Cost Effectiveness and Resource Allocation

IS - 1

ER -

Chen ZR, Chueh CH, Chiang NJ, Tsai YW. Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration. Cost Effectiveness and Resource Allocation. 2023 Sep 11;21(1). doi: 10.1186/s12962-023-00473-5